Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792122 | 0.83 | HDAC7 (0.59) | SMN1; SMN2KMT2AHTTFLT1FLT4 | |
| SCHEMBL4766299 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2KMT2ARAB9AKDM4EMMP13 | |
| SCHEMBL5504399 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2AHTTFLT1FLT4 | |
| SCHEMBL20418534 | 0.82 | TAS1R3 (0.55) | KDRRAB9ANPC1TAS1R3TAS1R1 | |
| SCHEMBL13273316 | 0.82 | HDAC6 (0.45) | SMN1; SMN2KMT2AHTTFLT1FLT4 | |
| SCHEMBL8318320 | 0.80 | FLT1 (0.59) | SMN1; SMN2KMT2AFLT1FLT4KDR | |
| SCHEMBL7706279 | 0.80 | HPGD (0.59) | SMN1; SMN2KMT2AFLT1FLT4KDR | |
| SCHEMBL1003542 | 0.80 | GAA (0.58) | SMN1; SMN2KMT2AHTTRAB9ANPC1 | |
| SCHEMBL22226016 | 0.80 | MAP2K1 (0.42) | SMN1; SMN2KMT2AHTTFLT1FLT4 | |
| SCHEMBL1697081 | 0.80 | FLT1 (0.54) | KMT2AFLT1FLT4KDRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| EP-0550557-B1 | DETERGENT CONTAINING ALKYL SULFATE AND POLYHYDROXY FATTY ACID AMIDE SURFACTANTS | PROCTER & GAMBLE (US) | 1996-03-20 | — | — | EP | claimed |
| US-20240409523-A1 | SUGAR AMIDES AND MIXTURES THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2024-12-12 | — | — | US | disclosed |
| EP-4408385-A1 | SUGAR AMIDES AND MIXTURES THEREOF | Clariant International Ltd (CH) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023065551-A1 | AGGREGATE FORMED BY MEANS OF ASSEMBLING CHALCOGEN HETEROCYCLIC COMPOUND AND INSULIN, AND PREPARATION METHOD THEREFOR, AND INSULIN ORAL PREPARATION | 福州大学 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023052616-A1 | SUGAR AMIDES AND MIXTURES THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2023-04-06 | — | — | WO | disclosed |
| US-20220008304-A1 | MIXED SUGAR COMPOSITIONS | PROCTER & GAMBLE (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3922247-A1 | 15-PGDH INHIBITOR | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-15 | — | — | EP | disclosed |
| US-9956548-B2 | Preparation of an olefin oligomerization catalyst | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2896613-B1 | SULFONAMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-2964740-B1 | MIXED SUGAR-BASED AMIDE SURFACTANT COMPOSITIONS | PROCTER & GAMBLE (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-0636625-B1 | Tricyclic diazepines vasopressin and oxytocin antagonists | AMERICAN CYANAMID CO (US) | 1999-01-27 | — | — | EP | disclosed |
| CN-1178523-A | Aminophenol derivatives | DIICHI PHARMACEUTICAL CO LTD (JP) | 1998-04-08 | — | — | CN | disclosed |
| US-4275213-A | Isoxazolyl derivatives of 9α,11α-epoxy imino-9,11,15-trideoxy-PGF-type compounds | THE UPJOHN COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
| US-4107311-A | ANTI-FERTILITY AGENTS, ABORTIFACIENTS | SANDOZ, INC. (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | SMN1; SMN2 2013/4885KMT2A 3931/4885HTT 2373/4885 |
| US-20220008304-A1 | MIXED SUGAR COMPOSITIONS | MGAM, ABHD6, PHOSPHO1 | SMN1; SMN2 669/4885KMT2A 865/4885HTT 1640/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | SMN1; SMN2 27/4885KMT2A 1240/4885HTT 2446/4885 |
| US-20240409523-A1 | SUGAR AMIDES AND MIXTURES THEREOF | UGCG, AMDHD2, MGAM | SMN1; SMN2 3743/4885KMT2A 631/4885HTT 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.